Instead of approving the new Alzheimer’s drug donanemab this month, as was expected, the U.S. Food and Drug Administration will now require the experimental medication be scrutinized more closely...
Timing of CSF biomarker divergence for Alzheimer’s disease, normal cognition varies
Feb 21, 2024
Estimated times of divergence of cerebrospinal fluid biomarkers vary from 18 years for Aβ42 to six years for cognitive decline.
Biogen is dropping controversial Alzheimer’s drug Aduhelm
Jan 31, 2024
Biogen said it will shift its focus to a newer Alzheimer’s drug, Leqembi, which it markets in a partnership with Japan-based Eisai. Leqembi received FDA approval last year.
AAN: Higher fitness level tied to lower Alzheimer’s disease risk
Feb 28, 2022
A graded association was seen between levels of cardiorespiratory fitness and the incidence of Alzheimer’s disease and related disorders.
Few older adults knowledgeable about aducanumab for Alzheimer’s disease
Feb 25, 2022
Less than one-quarter of older adults report they would want to take aducanumab (Aduhelm).
Women have higher tau, especially in setting of elevated Aβ
Apr 05, 2023
Later age at menopause and hormone therapy non-use also were associated with higher regional tau.
Vasomotor symptoms linked to increased risk for Alzheimer’s disease
Sep 27, 2023
Objectively assessed VMS (so-called hot flashes), including sleep VMS, are associated with significantly lower amyloid-β42/40.
Causal link ID’d for Alzheimer’s disease, generalized epilepsy
May 25, 2023
A genetic predisposition to Alzheimer’s also is linked to an increased risk of focal epilepsy with hippocampal sclerosis.
Allopurinol may cut risk for neurodegenerative diseases
May 19, 2023
Allopurinol linked to 13 to 34 percent lower risk for Parkinson disease, Alzheimer disease, ALS
One in three family caregivers for Alzheimer’s disease patients has depression
Oct 12, 2022
The authors say that the health of family caregivers should be monitored in clinical practices.